JANX vs LLY

Janux Therapeutics maintains significant 10x growth potential, underpinned by its innovative TRACTr platform and strategic focus on T-cell engagers for solid tumors and now autoimmune diseases. The Bristol Myers Squibb collaboration provides substantial validation and non-dilutive funding, bolstering its already strong cash position of approximately $1B. Anticipated clinical data readouts througho...

Eli Lilly remains a pharmaceutical powerhouse with exceptional market leadership, especially driven by its GLP-1 agonist franchise (Mounjaro/Zepbound). The company possesses a robust R&D pipeline and substantial competitive advantages through intellectual property and scale. While LLY offers strong long-term growth and stability, its current market capitalization exceeding $1 trillion makes achiev...